Unichem Laboratories has lined up a CapEx of around 350 crore for the next 2 years as it plans to strengthen R&D activity and expand operations in the US market. The company, which focuses on various therapeutic segments like gastroenterology and cardiology, expects its US revenues to cross 640 crore (USD 100 million) over the next few years. The long-term aim of the company is to cross 3200 crore (USD 500 million) in revenues from the US operations.


Digital version